Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up [0.03%]
关于ECHELON-2研究5年随访的布伦妥珠单抗维多汀联合化疗治疗一线系统性间变性大细胞淋巴瘤亚组分析
Eva Domingo-Domènech,Barbara Pro,Tim Illidge et al.
Eva Domingo-Domènech et al.
ClinicalTrials.gov number: NCT01777152. © 2025. The Author(s).
Multicenter Study
Blood cancer journal. 2025 Aug 1;15(1):129. DOI:10.1038/s41408-025-01329-2 2025
Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma [0.03%]
评估双特异性抗体在多发性骨髓瘤治疗中的不良事件谱系的全面分析
Mobina Golmohammadi,Shahzad Raza,Maram Albayyadhi et al.
Mobina Golmohammadi et al.
Bispecific antibodies (BsAbs) have shown promise in the management of relapsed/refractory multiple myeloma (MM). Despite its efficacy, this class of drugs is associated with significant toxicities. In this study, we conducted a pooled analy...
A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia [0.03%]
亚洲初级骨髓增生异常肿瘤的临床基因组预后模型
Harinder Gill,Rita Yim,Paul Lee et al.
Harinder Gill et al.
A personalized prognostic model that takes into account the unique molecular features of primary myelodysplastic neoplasm (MDS) in Asia patients is lacking. Diagnostic clinicopathologic features, cytogenetic changes, and gene mutations of e...
The SOX11:SMARCA4 complex is a driver of oncogenic transcriptional programs in mantle cell lymphoma [0.03%]
SOX11:SMARCA4复合体通过驱动套细胞淋巴瘤的致癌转录程序促进肿瘤发生
Anna De Bolòs,Maria Carreras-Caballé,Marta Sureda-Gómez et al.
Anna De Bolòs et al.
Mantle cell lymphoma (MCL) is considered one of the most aggressive B-cell lymphoid neoplasms. The transcription factor SOX11 is aberrantly expressed in conventional aggressive MCL, while it is not or weakly expressed in the leukemic non-no...
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement [0.03%]
CAR-T细胞和双特异性抗体在多发性骨髓瘤合并髓外病变中的活性研究
Maximilian J Steinhardt,Christoph Schaefers,Lisa B Leypoldt et al.
Maximilian J Steinhardt et al.
Extramedullary multiple myeloma (EMD) is associated with low response rates, short progression-free survival, and poor prognosis. CAR T cells and bispecific antibodies (bsABs) have shown efficacy in relapsed myeloma, but it remains uncertai...
Multicenter Study
Blood cancer journal. 2025 Jul 30;15(1):126. DOI:10.1038/s41408-025-01330-9 2025
Reconstructing CML guidelines for first line treatment from two different points of view [0.03%]
从两个不同角度重新构建CML一线治疗指南
Carlo Gambacorti-Passerini,Giulia Bassi,Stefano Bonfanti et al.
Carlo Gambacorti-Passerini et al.
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia [0.03%]
维奈克拉联合砷剂和全反式维甲酸治疗复发/难治性急性早幼粒细胞白血病患者
Bingqian Jiang,Hongyan Tong,Min Yang et al.
Bingqian Jiang et al.
Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma [0.03%]
MY-RADS在多发性骨髓瘤影像学评估中的作用：全身磁共振篇
Christina Messiou,Nuria Porta,Dow-Mu Koh et al.
Christina Messiou et al.
Minimal residual disease (MRD) testing has underpinned the evaluation and expansion of therapeutic options for patients with multiple myeloma (MM). Imaging is essential for evaluating residual disease status, overcoming sampling errors inhe...
Clinical Trial
Blood cancer journal. 2025 Jul 17;15(1):122. DOI:10.1038/s41408-025-01327-4 2025
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma [0.03%]
原发性睾丸弥漫大B细胞淋巴瘤的预后基因表达及微小核糖核酸谱型和遗传改变
Wenyu Shi,Zijun Y Xu-Monette,Youchao Jia et al.
Wenyu Shi et al.
Primary testicular (PT) diffuse large B-cell lymphoma (DLBCL) is a rare and aggressive lymphoma with distinct clinical and molecular characteristics. To identify prognostic biomarkers in PT-DLBCL, in this study we analyzed DNA and RNA sampl...
Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency [0.03%]
GATA2缺陷所致儿童MDS的年龄依赖性表型和分子进化特征分析
Lili Kotmayer,Emilia J Kozyra,Guolian Kang et al.
Lili Kotmayer et al.
GATA2 deficiency is an autosomal dominant transcriptopathy disorder with high risk for myelodysplastic syndrome (MDS). To elucidate genotype-phenotype associations and identify new genetic risk factors for MDS, we analyzed 218 individuals w...